Pharmaceutical

LY-3541860 by Eli Lilly and Co for Relapsing Multiple Sclerosis (RMS): Likelihood of Approval

LY-3541860 is under clinical development by Eli Lilly and Co and currently in Phase II for Relapsing Multiple Sclerosis (RMS).

May 17, 2024 - 04:00
LY-3541860 is under clinical development by Eli Lilly and Co and currently in Phase II for Relapsing Multiple Sclerosis (RMS).
Read the original article

Tags:

Previous Article

MRNA-1365 by Moderna for Human Metapneumovirus Infections: Likelihood of Approval

Next Article

LZ-901 by Beijing Luzhu Biotechnology for Herpes Zoster (Shingles): Likelihood o...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Biotech investors push to extend time before Medicare price negotiations; RiteAid closings could cause pharmacy deserts

STAT+: Pharmalittle: Biotech investors push to extend t...

Oct 18, 2023

STAT+: Drug companies and pharmacies reach $17.3 billion settlement over opioid crisis

STAT+: Drug companies and pharmacies reach $17.3 billio...

Jun 10, 2023

Abeona’s cell therapy secures priority approval date for rare skin disorder

Abeona’s cell therapy secures priority approval date fo...

Nov 28, 2023